![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
A more recent version of this article appeared on April 1, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 15, 2003
Revised on December 10, 2003
Accepted on December 22, 2003
1 Structural Cell Biology Unit, Department of Medical Anatomy, The Panum Institute, University of Copenhagen, Copenhagen 2200 N, Denmark
* Corresponding author. E-mail address: b.v.deurs{at}mai.ku.dk.
In contrast to the EGF receptor, ErbB2 is known to remain at the plasma membrane after ligand binding and dimerization. However, why ErbB2 is not efficiently down-regulated has remained elusive. Basically two possibilities exist: ErbB2 is internalization resistant or it is efficiently recycled after internalization. By a combination of confocal microscopy, immunogold labeling electron microscopy and biochemical techniques we here show that ErbB2 is preferentially associated with membrane protrusions. Moreover, it is efficiently excluded from clathrin-coated pits and is not seen in transferrin receptor (TfR)-containing endosomes. This pattern is not changed after binding of EGF, Heregulin, or Herceptin. The exclusion from coated pits is so pronounced that it cannot just be explained by lack of an internalization signal. Although ErbB2 is a raft-associated protein, the localization of ErbB2 to protrusions is not a result of raft-binding. Also, an intact actin cytoskeleton is not required for keeping ErbB2 away from coated pits. However, after efficient cross-linking, ErbB2 is removed from protrusions to appear on the bulk membrane, in coated pits, and in endosomes. These data show that ErbB2 is a remarkably internalization-resistant receptor and suggest that the mechanism underlying the firm association of ErbB2 with protrusions also is the reason for this resistance.
This article has been cited by other articles:
|
|
 |
|
  D. J. Barr, A. G. Ostermeyer-Fay, R. A. Matundan, and D. A. Brown Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells J. Cell Sci., October 1, 2008; 121(19): 3155 - 3166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Pedersen, I. H. Madshus, C. Haslekas, and E. Stang Geldanamycin-Induced Down-Regulation of ErbB2 from the Plasma Membrane Is Clathrin Dependent but Proteasomal Activity Independent Mol. Cancer Res., March 1, 2008; 6(3): 491 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Kumar, T. P. Quinn, and S. L. Deutscher Evaluation of an 111In-Radiolabeled Peptide as a Targeting and Imaging Agent for ErbB-2 Receptor Expressing Breast Carcinomas Clin. Cancer Res., October 15, 2007; 13(20): 6070 - 6079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lerdrup, S. Bruun, M. V. Grandal, K. Roepstorff, M. M. Kristensen, A. M. Hommelgaard, and B. van Deurs Endocytic Down-Regulation of ErbB2 Is Stimulated by Cleavage of Its C-Terminus Mol. Biol. Cell, September 1, 2007; 18(9): 3656 - 3666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Grandal, R. Zandi, M. W. Pedersen, B. M. Willumsen, B. van Deurs, and H. S. Poulsen EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes Carcinogenesis, July 1, 2007; 28(7): 1408 - 1417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Magnifico, L. Albano, S. Campaner, M. Campiglio, S. Pilotti, S. Menard, and E. Tagliabue Protein Kinase C{alpha} Determines HER2 Fate in Breast Carcinoma Cells with HER2 Protein Overexpression without Gene Amplification Cancer Res., June 1, 2007; 67(11): 5308 - 5317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Cao, X. Wu, L. Yen, C. Sweeney, and K. L. Carraway III Neuregulin-Induced ErbB3 Downregulation Is Mediated by a Protein Stability Cascade Involving the E3 Ubiquitin Ligase Nrdp1 Mol. Cell. Biol., March 15, 2007; 27(6): 2180 - 2188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. N.C. Chiu, L. A. Edwards, A. I. Kapanen, M. M. Malinen, W. H. Dragowska, C. Warburton, G. G. Chikh, K. Y.Y. Fang, S. Tan, J. Sy, et al. Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs Mol. Cancer Ther., March 1, 2007; 6(3): 844 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Wang, I. Shin, F. Y. Wu, D. B. Friedman, and C. L. Arteaga HER2/Neu (ErbB2) Signaling to Rac1-Pak1 Is Temporally and Spatially Modulated by Transforming Growth Factor {beta} Cancer Res., October 1, 2006; 66(19): 9591 - 9600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kultti, K. Rilla, R. Tiihonen, A. P. Spicer, R. H. Tammi, and M. I. Tammi Hyaluronan Synthesis Induces Microvillus-like Cell Surface Protrusions J. Biol. Chem., June 9, 2006; 281(23): 15821 - 15828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-H. Huang and S. L. Morrison A Trimeric Anti-HER2/neu ScFv and Tumor Necrosis Factor-{alpha} Fusion Protein Induces HER2/neu Signaling and Facilitates Repair of Injured Epithelia J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 983 - 991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lerdrup, A. M. Hommelgaard, M. Grandal, and B. van Deurs Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way J. Cell Sci., January 1, 2006; 119(1): 85 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Haslekas, K. Breen, K. W. Pedersen, L. E. Johannessen, E. Stang, and I. H. Madshus The Inhibitory Effect of ErbB2 on Epidermal Growth Factor-induced Formation of Clathrin-coated Pits Correlates with Retention of Epidermal Growth Factor Receptor-ErbB2 Oligomeric Complexes at the Plasma Membrane Mol. Biol. Cell, December 1, 2005; 16(12): 5832 - 5842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Benlimame, Q. He, S. Jie, D. Xiao, Y. J. Xu, M. Loignon, D. D. Schlaepfer, and M. A. Alaoui-Jamali FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion J. Cell Biol., November 7, 2005; 171(3): 505 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Perera, Y. Narita, F. B. Furnari, H. K. Gan, C. Murone, M. Ahlkvist, R. B. Luwor, A. W. Burgess, E. Stockert, A. A. Jungbluth, et al. Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor-Specific Antibody Generates Enhanced Antitumor Activity Clin. Cancer Res., September 1, 2005; 11(17): 6390 - 6399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Pegram Molecular Determinants of Trastuzumab Response/Resistance Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 155 - 159. [Full Text] [PDF]
|
|
|
|
|
|
S. Ghatak, S. Misra, and B. P. Toole Hyaluronan Constitutively Regulates ErbB2 Phosphorylation and Signaling Complex Formation in Carcinoma Cells J. Biol. Chem., March 11, 2005; 280(10): 8875 - 8883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Austin, A. M. De Maziere, P. I. Pisacane, S. M. van Dijk, C. Eigenbrot, M. X. Sliwkowski, J. Klumperman, and R. H. Scheller Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin Mol. Biol. Cell, December 1, 2004; 15(12): 5268 - 5282. [Abstract] [Full Text] [PDF]
|
|
